Related Experiment Video

Updated: Jun 16, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

Nathan T Ihle1, Garth Powis

  • 1Anderson Cancer Center, FC-6.3044, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Molecular Aspects of Medicine
|February 24, 2010
PubMed

Insights

Developing targeted cancer therapies requires careful consideration of the phosphatidylinositol-3-kinase (PI3K) pathway. This review examines PI3K inhibitors, discussing specificity versus broad-spectrum approaches for maximal therapeutic benefit.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol-3-kinase (PI3K) signaling pathway plays a crucial role in cancer development and progression.
  • Significant research efforts are focused on developing PI3K pathway inhibitors for therapeutic applications.
  • The complexity of the PI3K family presents challenges in designing effective inhibitors.

Purpose of the Study:

  • To review the development of agents targeting the PI3K pathway.
  • To discuss key issues in the development of PI3K inhibitors for clinical trials.
  • To explore the debate between specific versus broad-spectrum PI3K inhibition strategies.

Main Methods:

  • Literature review of PI3K inhibitors and their development.
  • Analysis of pharmacologic properties and clinical trial readiness.
  • Discussion of target specificity and pathway modulation.

Main Results:

  • The landscape of PI3K inhibitors has evolved from archetypal agents to numerous compounds targeting various PI3K family members.
  • Off-target properties of early inhibitors influenced pathway understanding.
  • Current research faces questions regarding optimal inhibitor specificity for therapeutic efficacy.

Conclusions:

  • The development of PI3K inhibitors requires careful consideration of target specificity to maximize therapeutic benefits.
  • Further research is needed to determine whether highly specific or broad-spectrum inhibitors will yield greater clinical efficacy.
  • Addressing pharmacologic properties is essential for advancing PI3K inhibitors to clinical trials.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...